Aktive Positionen von Tom Willis
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Tom Willis
Ehemalige bekannte Positionen von Tom Willis
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ADAPTIVE BIOTECHNOLOGIES CORPORATION | Direktor/Vorstandsmitglied | - | 01.01.2019 |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 2 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
Private Unternehmen | 1 |
---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Tom Willis
- Erfahrung